Table 2 Incidence rate of target events (venous thromboembolism, deep venous thrombosis)
From: Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma
Variable | Target event (n) | Incidence rate (95% CI) |
|---|---|---|
Mutation status: | ||
EGFR+ | 15 | 0.21 (0.10–0.32) |
ALK+ | 13 | 0.27 (0.13–0.42) |
Unexposed group | 25 | 0.22 (013–0.31) |
Gender: | ||
Female | 31 | 0.21 (0.14–0.29) |
Male | 22 | 0.26 (0.15–0.37) |
Age | ||
< 66 years | 38 | 0.33 (0.22–0.43) |
> 66 years | 15 | 0.13 (0.06–0.19) |
Stadium | ||
I | 4 | 0.05 (0.01–0.10) |
II | 6 | 0.21 (0.04–0.37) |
III | 9 | 0.18 (0.06–0.30) |
IV | 34 | 0.46 (0.30–0.61) |
Smoking status: | ||
Never smoker | 17 | 0.26 (0.14–0.38) |
Ex-smoker | 14 | 0.18 (0.11–0.26) |
Smoker | 22 | 0.26 (0.14–0.38) |
Hypertension | 12 | 0.14 (0.06–0.22) |
Diabetes | 0 | - |
AC before the event | 7 | 0.24 (0.06–0.42) |
Treatment options: | ||
CTP alone | 30 | 1.00 (0.55–1.45) |
Other treatment without TKI | 4 | 0.11 (0.05–0.17) |
Other treatment with TKI | 0.25 (0.13–0.38) | |
TKI alone | 19 | 0.15 (0.04–0.29) |